The stock has been a major outperformer lately amid the weakness in tech stocks.
Get this delivered to your inbox, and more info about our products and services.
Shares were down around 5% on Thursday afternoon despite a beat-and-raise quarter.
We're also bumping up our price target on shares.
The investment bank upgraded the pharma stock to overweight from equal weight.
While the results and the outlook were great, commentary on the post-earnings call proved to be the most crucia
The company's earnings report wasn't perfect, but the long-term story is still intact.
Bristol-Myers beats Q2 earnings and revenue estimates, driven by growth drugs, while raising its full-year 2026 sales and profit…
